OM-85 BV in pediatric recurrent respiratory tract infections: a cost-utility analysis

OM-85 BV in pediatric recurrent respiratory tract infections: a cost-utility analysis

Abstract Background Despite the growing evidence on efficacy, little is known regarding the cost-utility of Vaxom/Imocur (OM-85 BV) supplementation to decrease the probability of recurrent respiratory tract infections in OM-85 BV to reduce the incidence of recurrent respiratory tract infections in c...

Full description

Bibliographic Details
Main Authors: Jefferson Antonio Buendía, Diana Guerrero Patiño, Erika Fernanda Lindarte
Format: Article
Language:English
Published: BMC 2022-12-01
Series:BMC Pulmonary Medicine
Subjects:
Health economics
Public health
Healthcare
Colombia
Corticosteroids
Online Access:https://doi.org/10.1186/s12890-022-02264-9

Internet

https://doi.org/10.1186/s12890-022-02264-9

Similar Items